CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. The company describes itself as a full-service, non-clinical global drug development partner, supporting clients from target identification through non-clinical development and product release. Its operations are organized into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, revenue reached $4.0 billion, with DSA contributing 59.8%, RMS 21.1%, and Manufacturing 19.1%. The company runs more than 120 sites across over 20 countries, giving it a broad international footprint in preclinical research infrastructure.

Its scale and segment mix point to genuine competitive positioning in outsourced drug development, yet the current margin profile tells a more complicated story. Net margin is -6.0% and ROE is -7.7%, indicating that the business is not currently translating revenue into accounting profits despite its market leadership. With a market capitalization of $17.1 billion, Charles River is valued as a major player, but the negative profitability ratios suggest the company is absorbing costs—whether from restructuring, acquisitions, pricing pressure, or mix shifts—that are compressing returns. The moat from scale and scientific capability appears intact, but it is not currently showing up in bottom-line returns.

Financial posture

Charles River currently trades at a negative P/E of -73.4, a direct consequence of the -6.0% net margin rather than extreme overvaluation on a traditional earnings basis. A negative P/E typically signals that the market is either looking through temporary losses toward a recovery, or that investors are valuing the company on non-earnings metrics such as revenue, EBITDA, or strategic optionality. The -7.7% ROE reinforces that shareholders are not earning positive returns on book equity at this stage.

The stock’s beta is 1.40, meaning it has historically been about 40% more volatile than the overall market. That sensitivity is consistent with a company tied to biotech spending cycles, research outsourcing trends, and event-driven news flow. As of the snapshot date, CRL was at $355.24, with a 50-day EMA of $293.20 and an RSI of 75.9. The sharp gap between price and the 50-day moving average, combined with an RSI above 70, indicates the stock has moved swiftly relative to its recent range. These technical readings are worth contextualizing alongside the fundamental data, but they do not in themselves predict future direction.

Strategic priorities & outlook

The company’s most recent 10-K filing outlines a clear operational agenda centered on integration, footprint optimization, and scientific partnerships. Over the next two years, Charles River plans to close or consolidate approximately 12 additional sites, primarily within the DSA and RMS segments. That restructuring is aimed at simplifying operations and reducing fixed costs across a geographically dispersed network.

At the same time, management is merging Discovery Services and Safety Assessment into one unified DSA organization with a combined sales force and leadership structure. The stated goal is to operate as the “scientific partner of choice” by delivering a comprehensive and integrated portfolio that accelerates biomedical research and therapeutic innovation. Alongside internal consolidation, the company is pursuing expansion in Biologics Testing Solutions, adding service offerings and facilities in both the U.S. and Europe.

In January 2026, Charles River acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That acquisition ties directly into the company’s reliance on research model supply chains and indicates management is attempting to secure critical inputs even as it consolidates other parts of the global footprint.

Macro & geopolitical exposure

As a Healthcare company in Medical Diagnostics & Research, Charles River faces several macro and geopolitical sensitivities that are typical for the preclinical services industry. First, regulatory exposure is significant. Much of the company’s safety assessment work is governed by FDA, EMA, and other health authority guidelines, including Good Laboratory Practice (GLP) standards. Changes in regulatory requirements for preclinical testing can influence demand, study complexity, and compliance costs.

Second, the business is exposed to global supply chain and animal-source risks. The acquisition of non-human primate assets in Cambodia underscores the importance—and potential fragility—of research model supply chains. Trade restrictions, animal-welfare regulations, transport logistics, or disease outbreaks affecting research animal populations can directly affect both RMS and DSA operations.

Third, currency exposure matters for a company operating across more than 20 countries. Revenue and costs generated outside the U.S. create translation and transaction effects when converted back to dollars. Finally, the company is cyclically exposed to biotech and pharmaceutical funding. When capital is abundant, clients spend more on outsourced discovery and safety studies; when funding tightens, preclinical budgets often contract, pressuring utilization and pricing.

Recent developments

The most recent headlines provide a snapshot of how Charles River is interacting with investors, regulators, and scientific collaborators. On October 26, 2026, Seeking Alpha highlighted CRL in its “Ariel Fund Q3 2026 Leaders And Laggards” piece, suggesting the stock has drawn attention from managed-fund performance commentary. On October 22, 2026, Business Wire reported that Charles River, Labcorp, and the FDA are collaborating to validate new preclinical methods for abuse-potential assessment. That initiative matters because regulatory validation can create industry standards and potential competitive advantages for the participants.

On October 15, 2026, Defense World noted that the share price had crossed above its 200-day moving average, framing it within technical market commentary. Separately, on October 13, 2026, Business Wire announced a collaboration between Charles River and Magellan Stem Cells to advance stem cell and regenerative medicine development. That partnership fits the broader strategic emphasis on biologics and emerging therapeutic modalities.

Earnings behavior & post-earnings drift

Charles River has delivered a strong earnings track record by one metric: over the last eight reported quarters, the company beat estimates in all eight instances, for a 100% beat rate, with an average earnings surprise of 9.3%. The average 5-day price move following those reports was +1.24%, classified as an “up” drift. That suggests that, on average, the market has continued to reprice the stock positively in the days after results.

However, the last four quarters reveal meaningful dispersion beneath that average. The August 5, 2026 report delivered EPS of $3.02 against an estimate of $2.74, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five sessions. By contrast, the May 7, 2026 quarter produced EPS of $2.06 versus $1.96, a 5.1% beat, yet the stock fell 2.23% the next day and 12.42% over the next five days. The February 18, 2026 report showed a 2.6% surprise with a 3.95% next-day gain and 6.05% five-day gain, while the November 5, 2025 report produced a 4.7% surprise with a 1.9% next-day move and 2.27% five-day move.

The takeaway is that beating estimates has been the norm, but the magnitude and direction of the post-earnings reaction have varied. The next scheduled report is November 4, 2026, before the market open, with a consensus EPS estimate of $2.97. Given the 100% historical beat rate and the 9.3% average surprise, the market’s real expectation may be for a result above the published consensus, but recent quarters show that even a beat does not guarantee a positive price reaction.

For a deeper dive into how institutional analysts are interpreting these fundamentals, technical levels, and earnings dynamics, review the full institutional verdict on CRL.